Patient characteristics (N = 312)
| Characteristic . | No. (%) . |
|---|---|
| Median patient age at second-line treatment, range , y | 48 (1-73) |
| Patient gender | |
| Male | 175 (56) |
| Female | 137 (44) |
| Donor-patient gender combination | |
| Female to male | 89 (29) |
| Other | 223 (71) |
| Diagnosis | |
| Myeloid malignancy | 208 (67) |
| Lymphoid malignancy | 85 (27) |
| Other/nonmalignant | 19 (6) |
| Disease risk at transplantation* | |
| Low | 131 (42) |
| High | 181 (58) |
| Conditioning regimen | |
| High intensity without TBI | 135 (43) |
| High intensity with TBI | 75 (24) |
| Reduced intensity | 102 (33) |
| Graft source | |
| Bone marrow | 35 (11) |
| Mobilized blood cells | 265 (85) |
| Umbilical cord blood | 12 (4) |
| Donor and HLA type | |
| HLA-matched related | 130 (42) |
| HLA-matched unrelated | 118 (38) |
| HLA antigen or allele-mismatched related | 9 (3) |
| HLA antigen or allele-mismatched unrelated | 55 (18) |
| Median time from transplantation to initial systemic treatment, months (range) | 5.4 (2.2-29) |
| Initial systemic treatment | |
| Prednisone + CNI | 201 (64) |
| Prednisone + CNI + mycophenolate mofetil | 50 (16) |
| Prednisone alone | 37 (12) |
| Prednisone + others | 24 (8) |
| Characteristic . | No. (%) . |
|---|---|
| Median patient age at second-line treatment, range , y | 48 (1-73) |
| Patient gender | |
| Male | 175 (56) |
| Female | 137 (44) |
| Donor-patient gender combination | |
| Female to male | 89 (29) |
| Other | 223 (71) |
| Diagnosis | |
| Myeloid malignancy | 208 (67) |
| Lymphoid malignancy | 85 (27) |
| Other/nonmalignant | 19 (6) |
| Disease risk at transplantation* | |
| Low | 131 (42) |
| High | 181 (58) |
| Conditioning regimen | |
| High intensity without TBI | 135 (43) |
| High intensity with TBI | 75 (24) |
| Reduced intensity | 102 (33) |
| Graft source | |
| Bone marrow | 35 (11) |
| Mobilized blood cells | 265 (85) |
| Umbilical cord blood | 12 (4) |
| Donor and HLA type | |
| HLA-matched related | 130 (42) |
| HLA-matched unrelated | 118 (38) |
| HLA antigen or allele-mismatched related | 9 (3) |
| HLA antigen or allele-mismatched unrelated | 55 (18) |
| Median time from transplantation to initial systemic treatment, months (range) | 5.4 (2.2-29) |
| Initial systemic treatment | |
| Prednisone + CNI | 201 (64) |
| Prednisone + CNI + mycophenolate mofetil | 50 (16) |
| Prednisone alone | 37 (12) |
| Prednisone + others | 24 (8) |
TBI, total body irradiation; HLA, human leukocyte antigen; CNI, calcineurin inhibitor.
The low-risk category included chronic myeloid leukemia in chronic phase, acute leukemia in first remission, myelodysplastic syndrome without excess blasts, and nonmalignant diseases. The high-risk category included all other diseases and stages.